GSK Acquires Exclusive Rights for Prostate Cancer Treatment
GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical antibody drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).
Approximately 1.4 million men worldwide are diagnosed with prostate cancer each year, with 10-20% developing advanced disease within five years.
For patients with mCRPC, targeted treatment options are limited, and standard care options can be difficult to access and poorly tolerated, resulting in modest efficacy outcomes and low survival rates.
Survival rates for these patients are low, with a 5-year survival rate of approximately 30% and a median survival of approximately two years.
GSK's acquisition of exclusive rights aims to address this unmet need and improve treatment options for patients with mCRPC.
Author's summary: GSK gains exclusive rights to develop a prostate cancer treatment.
More News
- How is Financial Compensation Determined in a Car Accident?
- BlockDAG’s $0.0015 TGE Code Offers VIP Early Access, Outshining Ozak AI and Avalon X Presales
- Council facing £40m budget gap next year as officers warn savings need to be found
- Call For ‘Urgent Investigation’ After Cygnet Hotel Fire Response Criticised
- Bisphosphonates Reduce Fracture Risk in Prostate Cancer Patients on Androgen Deprivation Therapy, suggests study
- Binance & AAVE Show Signs of Slowdown While BlockDAG Climbs to $432M+ & Prepares For Genesis Day